KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Total Non-Current Liabilities (2018 - 2024)

Aurinia Pharmaceuticals (AUPH) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $150.6 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Total Non-Current Liabilities fell 1.46% year-over-year to $150.6 million, compared with a TTM value of $150.6 million through Sep 2024, down 1.46%, and an annual FY2023 reading of $159.2 million, up 199.12% over the prior year.
  • Total Non-Current Liabilities was $150.6 million for Q3 2024 at Aurinia Pharmaceuticals, up from $144.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $159.2 million in Q4 2023 and bottomed at -$465.5 million in Q1 2022.
  • Average Total Non-Current Liabilities over 4 years is $45.9 million, with a median of $49.0 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities plummeted 1707.95% in 2022, then surged 251.66% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $48.3 million in 2021, then rose by 10.25% to $53.2 million in 2022, then soared by 199.12% to $159.2 million in 2023, then fell by 5.43% to $150.6 million in 2024.
  • Business Quant data shows Total Non-Current Liabilities for AUPH at $150.6 million in Q3 2024, $144.9 million in Q1 2024, and $159.2 million in Q4 2023.